Wiki-Bio

Activity: Cell Activity
Expression system: HEK293 Cells
Length: 1-232, Full Length

Cetuximab (C225) is a monoclonal antibody that is an inhibitor of human epidermal growth factor receptor (EGFR) (Kd=0.201 nM). Cetuximab has antitumor activity, inhibiting tumor cell proliferation and inducing apoptosis.

Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate functioning as a HER2-targeted topoisomerase I inhibitor, with targeting capability and antitumor activity, employed in research on HER2-positive breast cancer and gastric cancer.

Anti-Mouse PD-1 Antibody (RMP1-14) is an IgG2a antibody inhibitor against mouse PD-1 and can block PD-1/PD-L1 signaling.

Activity: Cell Activity
Expression system: E. coli
Length: 23-140, Partial

Activity: ELISA, Cell Activity
Expression system: HEK293 Cells
Length: 1-262, Partial

Activity: Organoid Coculture, Cell Activity
Expression system: E. coli
Length: 971-1023, Partial

Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has been clinically used to treat HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer.

Activity: Organoid Coculture
Expression system: E. coli
Length: 32-194, Full Length of Mature Protein

Activity: ELISA
Expression system: E. coli
Length: 129-247, Full Length of Mature Protein

Activity: Cell Activity
Expression system: HEK293 Cells
Length: 35-146, Partial

Activity: Cell Activity
Expression system: E. coli
Length: 82-190, Full Length of Mature Protein

Activity: Cell Activity
Expression system: HEK293 Cells
Length: 279-390, Partial

Activity: Not Tested
Expression system: E. coli
Length: 1-495, Full Length

Activity: BLI, ELISA
Expression system: HEK293 Cells
Length: 27-191, Full Length of Mature Protein of Isoform VEGF165

Activity: Organoid Coculture, Cell Activity
Expression system: HEK293 Cells
Length: 311-426, Full Length of Mature Protein

Activity: ELISA
Expression system: HEK293 Cells
Length: 24-161, Full Length of Mature Protein

Activity: Cell Activity
Expression system: HEK293 Cells
Length: 279-390

Activity: Organoid Coculture, Cell Activity
Expression system: E. coli
Length: 143-288, Full Length of Mature Protein of Isoform 1

Activity: BLI, ELISA, Cell Activity
Expression system: E. coli
Length: 30-212, Full Length of Mature Protein

Activity: SPR, Cell Activity
Expression system: E. coli
Length: 77-233, Partial

Activity: Organoid Coculture, Cell Activity
Expression system: E. coli
Length: 38-208, Full Length of Mature Protein

Activity: ELISA
Expression system: HEK293 Cells
Length: 30-390 & 279-390, Full Length

Activity: Cell Activity
Expression system: E. coli
Length: 80-235, soluble form

Activity: Cell Activity
Expression system: CHO Cells
Length: 1-166, Full Length

Activity: Enzyme Activity
Expression system: Baculovirus Insect Cells
Length: 1-604, Full Length

Activity: Cell Activity
Expression system: E. coli
Length: 25-153, Full Length of Mature Protein

Activity: Cell Activity
Expression system: E. coli
Length: 118-269, Full Length of Mature Protein

Activity: Organoid Coculture, Cell Activity
Expression system: CHO Cells
Length: 279-390, Partial

Activity: ELISA, Cell Activity
Expression system: E. coli
Length: 21-169, Full Length of Mature Protein

Activity: Cell Activity
Expression system: HEK293 Cells
Length: 1-131, Full Length

Activity: Cell Activity
Expression system: CHO Cells
Length: 1-265, Full Length

Activity: Cell Activity
Expression system: E. coli
Length: 25-211, Full Length of Mature Protein

Activity: ELISA, Cell Activity
Expression system: HEK293 Cells
Length: 1-155, Full Length

Activity: ELISA, Cell Activity
Expression system: HEK293 Cells
Length: 1-196 & 1-335, Full Length

Activity: Organoid Coculture, Cell Activity
Expression system: CHO Cells
Length: 1-263, Full Length

Activity: Cell Activity
Expression system: HEK293 Cells
Length: 1-141, Full Length

Activity: Cell Activity
Expression system: E. coli
Length: 293-408 (mutation), Full Length of Mature Protein

Activity: ELISA, Organoid Coculture, Cell Activity
Expression system: E. coli
Length: 49-118, Full Length of Mature Protein

Activity: Cell Activity
Expression system: HEK293 Cells

Activity: BLI, Cell Activity
Expression system: HEK293 Cells
Length: 25-153, Full Length of Mature Protein

Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR).

Infliximab is a monoclonal antibody, a human-mouse chimeric monoclonal antibody that inhibits TNF-α and prevents TNF-α from interacting with TNFR1 and TNFR2. Infliximab can be used to treat Crohn's disease and rheumatoid arthritis.

Evolocumab is an inhibitor of the humanized monoclonal antibody PCSK9. It binds to circulating PCSK9 protein, resulting in inhibition of PCSK9 binding to LDLR. It can be used in studies of hypercholesterolemia and atherosclerotic cardiovascular disease.

Alirocumab is a human monoclonal antibody that inhibits PCSK9. It is produced by recombinant DNA technology in Chinese hamster ovary cell suspension culture.

Tocilizumab (Anti-Human IL6R) is a neutralizing antibody against human interleukin-6 receptor (IL-6R) that blocks the binding of IL-6 to IL-6R, thereby inhibiting both classical and trans signaling. It can be used to study rheumatoid arthritis and has been suggested as a possible drug for the treatment of severe COVID-19.

Rituximab is an anti-CD20 chimeric monoclonal antibody used to study certain autoimmune diseases and cancers.

Pertuzumab (anti-HER2) a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors impairs the ability of HER2 to bind to other members of the HER family.

Pembrolizumab (MK-3475) is a highly selective humanized monoclonal antibody that antagonizes PD-1. It can block the PD-1 protein on T cells and prevent their interaction with PD-L1 on cancer cells.

Nivolumab is a monoclonal antibody and is a humanized PD-1 antibody. Nivolumab has anti-tumor activity and is used in the treatment of melanoma, non-small cell lung cancer, renal cell carcinoma, etc.

Ipilimumab (Yervoy) is an antibody inhibitor that blocks the inhibitory receptor cytotoxic T-lymphocyte antigen-4 (CTLA-4) on T cells, with immune-activating properties. Used for the treatment of unresectable or metastatic melanoma, this antibody exhibits antitumor activity.

Bevacizumab, a humanized monoclonal antibody, specifically and with high affinity binds to all isoforms of VEGF-A.

Avelumab is a humanized anti-PD-L1 monoclonal antibody that binds to PD-L1 with high specificity (Kd = 0.1 nM) and exhibits potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab exerts a dual mechanism of action, combining direct antitumor activity with ADCC. Avelumab is used in research on cancers such as Merkel cell carcinoma.

Atezolizumab is an antibody inhibitor, a humanized monoclonal antibody, IgG1, which targets PD-L1 and blocks the interaction of PD-L1 with PD-1. Atezolizumab has antitumor activity and promotes T-cells to attack tumor cells.

Zolbetuximab(IMAB362) is a monoclonal antibody that specifically targets Claudin-18.2.Zolbetuximab has potential antitumor activity, mediating killing of Claudin-18.2-positive cells through an immune effector mechanism.Zolbetuximab is used in the study of gastrointestinal adenocarcinomas and pancreatic tumors.

Adalimumab (anti-TNF-alpha) is the first fully human recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha.

Anti-Mouse PD-L1 Antibody (10F.9G2) is an IgG-class antibody against mouse PD-L1.

Human IgG1 kappa, Isotype Control is a humanized IgG-like monoclonal antibody and an isotype control antibody for human IgG1κ.

Mirvetuximab soravtansine (IMGN853) is an antibody-drug coupling (ADC) targeting folate receptor alpha (FRα), which inhibits cell growth and enhances the antiproliferative effects of DNA damage, and may be useful in the study of drug-resistant ovarian cancer.

Sacituzumab govitecan (IMMU-132) is a humanized ADC compound targeting Trop-2 with anticancer activity for the study of refractory, locally advanced or metastatic breast cancer and uroepithelial cancer.

Amivantamab (Anti-c-Met) is a human antibody that recognizes the MET proto-oncogene (MET) and can be used in cancer-related research.

Lecanemab (BAN-2401) is an IgG1 monoclonal antibody targeting soluble aggregated β-amyloid (Abeta) with activity against oligomers, protofibrils, and insoluble protofibrils, and may be useful in the study of Alzheimer's disease (AD)-induced mild cognitive impairment and mild AD dementia.

Bimagrumab (BYM338) is a human monoclonal antibody that binds to the activin type II receptor. Bimagrumab can be used to study diabetes and obesity.

Ponsegromab (PF 06946860) is a selective and potent humanized anti-GDF15 antibody inhibitor with IC₅₀ values of 0.123 nM, 0.053 nM, and 0.102 nM for human, rhesus macaque, and mouse targets, respectively. Ponsegromab exhibits anti-cachexia activity by binding to GDF15 to prevent its interaction with GFRAL, thereby disrupting GDF15/GFRAL-mediated signaling. Ponsegromab possesses potential anticancer activity and may be used to treat cancer patients with cancer anorexia-cachexia syndrome. Ponsegromab acts as a chemopreparative agent, increasing intracellular reactive oxygen species levels and reducing glutathione levels.

Brentuximab vedotin (SGN-35) is a CD30-targeting antibody-active molecule conjugate (ADC) that combines a CD30 monoclonal antibody with the microtubule disrupting agent monomethylauristatin E for the study of lymphoma.

Olamkicept (FE-301) is a soluble gp130-Fc-fusion protein that selectively inhibits interleukin 6 (IL-6) trans-signaling by binding to the soluble IL-6 receptor/IL-6 complex.

Datopotamab deruxtecan (DS-1062) is an antibody-drug conjugate (ADC) that targets tropomyosin 2 (TROP2) on the surface of trophoblast cells. Datopotamab deruxtecan exhibits antitumor activity by specifically binding to TROP2 and internalizing, releasing DXd to inhibit topoisomerase I (IC₅₀ = 0.31 μM), thereby inducing DNA damage and apoptosis. Datopotamab deruxtecan induces significant antibody-dependent cellular cytotoxicity in the presence of peripheral blood lymphocytes and inhibits tumor growth in xenograft models.

Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) and a HER2-targeted cytotoxic agent, consisting of an anti-HER2 monoclonal antibody conjugated to MMAE via a cleavable linker, used for the treatment of HER2-expressing solid tumors including gastric cancer, breast cancer, and urothelial carcinoma.

Etanercept is a fusion protein consisting of the soluble portion of the p75-tumor necrosis factor receptor (TNFR) and the Fc fragment of human IgG1 and is commonly used to treat patients with rheumatoid arthritis.[1]

Sacituzumab (hRS7) is an antibody inhibitor and a humanized monoclonal antibody targeting trophoblast cell surface antigen 2 (TROP2), serving as a component of the antibody-drug conjugate sacituzumab govitecan, used for research and treatment of TROP2-high-expressing tumors such as triple-negative breast cancer.

Magrolimab (Hu5F9-G4) is a humanized anti-CD47 IgG4 monoclonal antibody that exhibits antitumor activity by blocking CD47 and binding primarily to the N-terminal pyroglutamate of CD47. It can be used in combination with other compounds for the treatment of recurrent myeloma.

Dupilumab (REGN-668) belongs to antibody inhibitors and is an IL-4Rα-targeted inhibitor that exerts anti-inflammatory effects by blocking IL-4 and IL-13 signaling. This compound possesses high selectivity and is mainly used for the treatment of moderate-to-severe atopic dermatitis.

Anakinra (Raleukin) is a cytokine inactivator and interleukin 1 receptor antagonist that can be used to study secondary phagocytic lymphohistiocytosis and rheumatoid arthritis.